Can You Make Ketamine…Boring?
Alar Pharmaceuticals reports positive Phase 1 results for long-acting injectable ketamine ALA-3000 in treatment-resistant depression.
Category Voyager Articles
Affinia Continues To Accumulate Wins
Affinia Therapeutics gets Health Canada nod for UPBEAT gene therapy trial in BAG3 cardiomyopathy.
The Denali Diaspora Hits the Clinic
Tenvie Therapeutics doses first patient in Phase 1 trial of CNS-penetrant NLRP3 inhibitor TNV262.
A Hundred Million Reasons to Pay Attention
Stipple Bio emerges from stealth with an oversubscribed $100M Series A to advance its precision oncology ADC platform.
One Bought a Podcast. The Other Bought a Lab.
Anthropic dropped $400M on a 9-person biotech AI startup. The same day, OpenAI bought a podcast. That tells you everything.
Seaport Therapeutics Shows 6.8x Bioavailability Boost With Anxiety Drug Prodrug
GlyphAgo took a European antidepressant the FDA rejected over liver toxicity — and may have solved both problems at once.
CanWell Pharma Gets FDA Nod for Dual-Payload ADC Aimed at Resistant HER2 Tumors
CAN016 carries two payloads in one antibody — designed specifically for patients who already failed ADC-based therapies.
Canada Bets $280M on Aspect Biosystems’ Bioprinted Tissue Therapeutics
Aspect Biosystems just landed $280M from the Canadian government to advance bioprinted cellular medicines — on top of a $115M Series B and a $2.7B Novo Nordisk deal.
Neutrolis Posts Positive Phase 1a Data for First-in-Class NET-Targeting Therapy
NTR-1011 is the first drug designed to dismantle neutrophil extracellular traps — and early safety data just cleared the way for lupus and RA patients.
A University Built a CAR-T Therapy From Scratch — And the FDA Said Yes
The University of Colorado Anschutz Gates Institute just became the first U.S. academic institution to take a fully in-house CAR-T from bench to IND — no pharma partner needed.